ANAVEX LIFE SCIENCES CORP. Q2 FY2024 earnings call

• Advancement of clinical programs: Phase 2b/3 blarcamesine (ANAVEX®2-73) for Alzheimer's disease with results presented at AAIC, submission of MAA to EMA in Q4 2024, RNA-seq analysis underway, ATTENTION-AD open-label extension 96-week trial interim data expected in second half 2024. • Phase 2 trial of ANAVEX®3-71 in schizophrenia: Completed dosing of first cohort, nearing completion of second cohort enrollment in Part A. • Parkinson disease: Initiation of Phase 2b/3 trial of ANAVEX®2-73 expected in second half 2024. • Rett Syndrome: Positive feedback from 2024 IRSF meeting, plans for larger study. • Fragile X: Biomarker data presented at conference, Phase 2/3 trial initiation planned. • Building medical affairs capabilities to expand education and physician support activities.

• Submission of MAA to EMA for blarcamesine expected in Q4 2024. • Interim data from RNA-seq and ATTENTION-AD open-label extension trial expected in second half 2024. • Initiation of Parkinson disease Phase 2b/3 trial in second half 2024. • Plans for larger Rett Syndrome trial and Phase 2/3 trial in a new rare disease.

• Uncertainty in clinical trial results and regulatory approvals. • Need for future capital to fund development. • Maintenance of intellectual property rights.

Q: What are your plans to meet with the FDA or regulators in Asia, and is there a date set?

A: Focus on email submission for regulatory package, no set date yet, will meet regulatory bodies globally when ready.

Q: Varying number of patients in AAIC data presentation?

A: Due to patient visit variability, consistent with other trials, every patient doesn't always attend at the same time point.

Q: $150 million stock offering?

A: Shelf offering for future needs, not for immediate use.

Q: Rett Syndrome trial initiation date?

A: No date yet, proceeding with larger study as planned.

Q: Fragile X Phase 1?

A: Phase 1 done with blarcamesine (ANAVEX®2-73) in healthy volunteers.

Q: Schizophrenia trial details?

A: Part A is signal ascending doses, second cohort nearing enrollment completion, Part B is longitudinal study.

Q: AAIC data dose dependency?

A: Dose response confirmed, adverse events like dizziness manageable with flexible titration.

Q: Open label 96 week data from ATTENTION-AD?

A: Data to be compiled, decision on next steps regarding FDA approach after data is ready.